Abstract
Soft tissue sarcomas (STS) are a heterogeneous group of malignant tumors of mesenchymal origin, accounting for less than 1% of all adult malignancies and 15% of pediatric cancers. The most common subtypes in adults are liposarcoma (which corresponds to 20% of all STS), leiomyosarcoma and undifferentiated pleomorphic sarcoma. Based on the pattern of dissemination and the risk of distant metastases a different imaging approach may be indicated for each STS subtype as a staging workup. However, a contrast enhanced chest computed tomography is recommended for all moderate or high grade STS as a baseline imaging. Surgery is the main treatment of localized STS. It is recommended that the resection of the primary tumor includes a 2 cm margin envelope of normal tissue surrounding the lesion. The indications for radiotherapy include: high grade tumors, large (>5 cm) proximal grade 2 tumors, head and neck STS, large or high grade retroperitoneal sarcomas, local recurrences or positive margins after surgery. Adjuvant chemotherapy is still not a consensus, but there are some histologies that are better responders, like: synovial sarcoma, myxoid or pleomorphic liposarcoma, leiomyosarcoma and undifferentiated pleomorphic sarcoma. Metastatic soft tissue sarcomas are basically treated with chemotherapy. However, as there is not any highly effective treatment for the metastatic disease, the prognostic factors for prolonged survival are more related to the tumor biology than to the treatment itself.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Miller RW, Young JL Jr, Novakovic B (1995) Childhood cancer. Cancer 75:395
Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (2013) World health organization classification of tumours of soft tissue and bone, 4th edn. IARC Press, Lyon
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7
DeVita VT, Lawrence TS (2011) Rosenberg SA Cancer: principles & practice of oncology, 9th edn. Wolters Kluwer Health/Lippincott. Williams & Wilkins, Philadelphia, p c201
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2017) SEER cancer statistics review, 1975–2014. National Cancer Institute, Bethesda
Brennan MF, Antonescu CR, Alektiar KM et al (2016) General description. In: Management of soft tissue sarcoma. Springer, New York, pp 6–8
Brennan MF, Antonescu CR, Moraco N et al (2014) Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg 260(3):416–422
Stacy GS, Dixon LB (2007) Pitfalls in MR image interpretation prompting referrals to an orthopedic oncology clinic. Radiographics 27:805–828
Henderson TO, Whitton J, Stovall M et al (2007) Secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. J Natl Cancer Inst 99(4):300–308
Riad S, Biau D, Holt GE et al (2012) The clinical and functional outcome for patients with radiation-induced soft tissue sarcoma. Cancer 118(10):2682–2692
Cahan WG, Woodard HQ, Higinbotham NL et al (1948) Sarcoma arising in irradiated bone; report of 11 cases. Cancer 1(1):3–29
Arlen M, Higinbotham NL, Huvos AG et al (1971) Radiation-induced sarcoma of bone. Cancer 28(5):1087–1099
Robinson E, Bleakney RR, Ferguson PC et al (2008) Oncodiagnosis panel: 2007 multidisciplinary management of soft tissue sarcoma. Radiographics 28:2069–2086
Aga P, Singh R, Parihar A et al (2011) Imaging spectrum in soft tissue sarcomas. Indian J Surg Oncol 2(4):271–279
Amini B, Jessop AC, Ganeshan DM et al (2015) Contemporary imaging of soft tissue sarcomas. J Surg Oncol 111:496–503
Knapp EL, Kransdorf MJ, Letson GD (2005) Diagnostic imaging update: soft tissue sarcomas. Cancer Control 12(1):22–26
Varma DG (1999) Optimal radiologic imaging of soft tissue sarcomas. Semin Surg Oncol 17(1):2–10
Gilbert NF, Cannon CP, Lin PP et al (2009) Soft-tissue sarcoma. J Am Acad Orthop Surg 17(1):40–47
Caracciolo JT, Letson GD (2016) Radiologic approach to bone and soft tissue sarcomas. Surg Clin North Am 96(5):963–976
Verheijen P, Witjes H, van Gorp J, Hennipman A, van Dalen T (2010) Current pathology work-up of extremity soft tissue sarcomas, evaluation of the validity of different techniques. Eur J Surg Oncol 36(1):95–99
Heslin MJ, Lewis JJ, Woodruff JM, Brennan MF (1997) Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol 4(5):425–431
Strauss DC, Qureshi YA, Hayes AJ, Thway K, Fisher C, Thomas JM (2010) The role of core needle biopsy in the diagnosis of suspected soft tissue tumours. J Surg Oncol 102(5):523–529
Woon DT, Serpell JW (2008) Preoperative core biopsy of soft tissue tumours facilitates their surgical management: a 10-year update. ANZ J Surg 78(11):977–981
Serpell JW, Pitcher ME (1998) Pre-operative core biopsy of soft-tissue tumours facilitates their surgical management. Aust N Z J Surg 68(5):345–349
Jaques DP, Coit DG, Casper ES, Brennan MF (1995) Hepatic metastases from soft-tissue Sarcoma. Ann Surg 221(4):392–397
Bold R, Benjamin R, Feig B, Hunt KK, Pearlstone DB, Pisters PW, Patel S, Pollack A, Pollock RE, Yasko AW (1999) Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. Cancer 85(1):85–92
Eilber FR, Eckardt J (1997) Surgical management of soft tissue sarcomas. Semin Oncol 24(5):526–533
Tanabe KK, Pollock RE, Ellis LM, Murphy A, Sherman N, Romsdahl MM (1994) Influence of surgical margins on outcome in patients with preoperatively irradiated extremity soft tissue sarcomas. Cancer 73(6):1652–1659
Ferguson PC, Griffin AM, O’Sullivan B, Catton CN, Davis AM, Murji A, Bell RS, Wunder JS (2006) Bone invasion in extremity soft-tissue sarcoma: impact on disease outcomes. Cancer 106(12):2692–2700
Cannon CP, Ballo MT, Zagars GK, Mirza AN, Lin PP, Lewis VO, Yasko AW, Benjamin RS, Pisters PW (2006) Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas. Cancer 107(10):2455–2461
Holt GE, Griffin AM, Pintilie M, Wunder JS, Catton C, O’Sullivan B, Bell RS (2005) Fractures following radiotherapy and limb-salvage surgery for lower extremity soft-tissue sarcomas. A comparison of high-dose and low-dose radiotherapy. J Bone Joint Surg Am 87(2):315–319
Gortzak Y, Lockwood GA, Mahendra A, Wang Y, Chung PW, Catton CN, O’Sullivan B, Deheshi BM, Wunder JS, Ferguson PC (2010) Prediction of pathologic fracture risk of the femur after combined modality treatment of soft tissue sarcoma of the thigh. Cancer 116(6):1553–1559
Nishinari K, Krutman M, Aguiar Junior S, Pignataro BS, Yazbek G, Zottele Bomfim GA, Teivelis MP, Wolosker N (2015) Surgical outcomes of vascular reconstruction in soft tissue sarcomas of the lower extremities. J Vasc Surg 62(1):143–149
Crago AM, Lee AY (2016) Multimodality management of soft tissue tumors in the extremity. Surg Clin North Am 96(5):977–992
Andreou D, Boldt H, Werner M et al (2013) Sentinel node biopsy in soft tissue sarcoma subtypes with a high propensity for regional lymphatic spread: results of a large prospective trial. Ann Oncol 24(5):1400–1405
Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM (2006) Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 106(8):1776–1784
Pennacchioli E, Deraco M, Mariani L, Fiore M, Mussi C, Collini P, Olmi P, Casali PG, Santinami M, Gronchi A (2007) Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol 14(2):553–559
Brady MS, Brown K, Patel A, Fisher C, Marx W (2009) Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Melanoma Res 19(2):106–111
Wagner MJ, Amodu LI, Duh MS et al (2015) A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments. BMC Cancer 15:175
Predina JD, Puc MM, Bergey MR et al (2011) Improved survival after pulmonary metastasectomy for soft tissue sarcoma. J Thorac Oncol 6:913–919
Leahy M, Garcia Del Muro X, Reichardt P et al (2012) Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The Sarcoma treatment and burden of illness in North America and Europe (SABINE) study. Ann Oncol 23:2763–2770
Gossot D, Radu C, Girard P et al (2009) Resection of pulmonary metastases from sarcoma: can some patients benefit from a less invasive approach? Ann Thorac Surg 87:238–243
Cardona K, Williams R, Movva S (2013) Multimodality therapy for advanced or metastatic sarcoma. Curr Probl Cancer 37:74–86
Kim S, Ott HC, Wright CD et al (2011) Pulmonary resection of metastatic sarcoma: prognostic factors associated with improved outcomes. Ann Thorac Surg 92:1780–1787
Weiser MR, Downey RJ, Leung DH et al (2000) Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg 191(2):184–190
Pastorino U, Buyse M, Friedel G et al (1997) Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 113:37–49
van Geel AN, Pastorino U, Jauch KW et al (1996) Surgical treatment of lung metastases: the European organization for research and treatment of cancer-soft tissue and bone sarcoma group study of 255 patients. Cancer 77:675–682
Rehders A, Hosch SB, Scheunemann P, Stoecklein NH, Knoefel WT, Peiper M (2007) Benefit of surgical treatment of lung metastasis in soft tissue sarcoma. Arch Surg 142:70–75
Smith R, Pak Y, Kraybill W, Kane JM III (2009) Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy. Eur J Surg Oncol 35:356–361
Blackmon SH, Shah N, Roth JA, Correa AM, Vaporciyan AA, Rice DC et al (2009) Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg 88:877–884
Lin AY, Kotova S, Yanagawa J, Elbuluk O, Wang G, Kar N et al (2015) Risk stratification of patients undergoing pulmonary metastasectomy for soft tissue and bone sarcomas. J Thorac Cardiovasc Surg 149:85–92
Smith R, Demmy TL (2012) Pulmonary metastasectomy for soft tissue sarcoma. Surg Oncol Clin N Am 21:269–286
McCormack PM, Ginsberg KB, Bains MS, Burt ME, Martini N, Rusch VW et al (1993) Accuracy of lung imaging in metastases with implications for the role of thoracoscopy. Ann Thorac Surg 56:863–865
Chudgar NP, Brennan MF, Munhoz RR, Bucciarelli PR, Tan KS, D’Angelo SP, Bains MS, Bott M, Huang J, Park BJ, Rusch VW, Adusumilli PS, Tap WD, Singer S, Jones DR (2017) Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. J Thorac Cardiovasc Surg 154(1):319–330.e1
Ferguson PC, Deheshi BM, Chung P, Catton CN, O’Sullivan B, Gupta A, Griffin AM, Wunder JS (2011) Soft tissue sarcoma presenting with metastatic disease: outcome with primary surgical resection. Cancer 117(2):372–379
Keung EZ, Fairweather M, Raut CP (2016) Surgical management of metastatic disease. Surg Clin North Am 96(5):1175–1192
Yedibela S, Gohl J, Graz V et al (2005) Changes in indication and results after resection of hepatic metastases from noncolorectal primary tumors: a single-institutional review. Ann Surg Oncol 12:778–785
Lang H, Nussbaum KT, Kaudel P et al (2000) Hepatic metastases from leiomyosarcoma a single-center experience with 34 liver resections during a 15-year period. Ann Surg 231(4):500–505
Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, DeMoss EV, Seipp C, Sindelar WF, Sugarbaker P, Wesley R (1982) The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 196(3):305–315
Williard WC, Hajdu SI, Casper ES, Brennan MF (1992) Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 215(3):269–275
LeVay J, O’Sullivan B, Catton C, Bell R, Fornasier V, Cummings B, Hao Y, Warr D, Quirt I (1993) Outcome and prognostic factors in soft tissue sarcoma in the adult. Int J Radiat Oncol Biol Phys 27(5):1091–1099
Manoso MW, Frassica DA, Deune EG, Frassica FJ (2005) Outcomes of re-excision after unplanned excisions of soft-tissue sarcomas. J Surg Oncol 91(3):153–158
McNeer GP, Cantin J, Chu F, Nickson JJ (1968) Effectiveness of radiation therapy in the management of sarcoma of the soft somatic tissues. Cancer 22(2):391–397
Canter RJ, Beal S, Borys D, Martinez SR, Bold RJ, Robbins AS (2010) Interaction of histologic subtype and histologic grade in predicting survival for soft-tissue sarcomas. J Am Coll Surg 210(2):191–198.e2
Kuklo TR, Temple HT, Owens BD, Juliano J, Islinger RB, Andejeski Y, Frassica DA, Berrey BH (2005) Preoperative versus postoperative radiation therapy for soft-tissue sarcomas. Am J Orthop (Belle Mead NJ) 34(2):75–80
Al-Absi E, Farrokhyar F, Sharma R, Whelan K, Corbett T, Patel M, Ghert M (2010) A systematic review and meta-analysis of oncologic outcomes of pre- versus postoperative radiation in localized resectable soft-tissue sarcoma. Ann Surg Oncol 17(5):1367–1374
Sampath S, Schultheiss TE, Hitchcock YJ, Randall RL, Shrieve DC, Wong JY (2011) Preoperative versus postoperative radiotherapy in soft-tissue sarcoma: multi-institutional analysis of 821 patients. Int J Radiat Oncol Biol Phys 81(2):498–505
Sarcoma Meta-Analysis Collaboration (1997) Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma meta-analysis collaboration. Lancet 350(9092):1647–1654
Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M (2008) A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113(3):573–581
Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P (2001) Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19(5):1238–1247
Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, Leahy M, Van Coevorden F, Verweij J, Hogendoorn PC, Ouali M, Marreaud S, Bramwell VH, Hohenberger P (2012) EORTC soft tissue and bone sarcoma group and the NCIC Clinical trials group sarcoma disease site committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 13(10):1045–1054
Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, Casali PG (2004) Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 101(3):627–634
Cormier JN, Huang X, Xing Y, Thall PF, Wang X, Benjamin RS, Pollock RE, Antonescu CR, Maki RG, Brennan MF, Pisters PW (2004) Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol 22(22):4567–4574
Eilber FC, Eilber FR, Eckardt J, Rosen G, Riedel E, Maki RG, Brennan MF, Singer S (2004) The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 240(4):686–695. discussion 695–7
Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG, Picci P (2012) Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian sarcoma group and the Spanish sarcoma group. J Clin Oncol 30(8):850–856
Meric F, Milas M, Hunt KK, Hess KR, Pisters PW, Hildebrandt G, Patel SR, Benjamin RS, Plager C, Papadopolous NE, Burgess MA, Pollock RE, Feig BW (2000) Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol 18(19):3378–3383
Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG (2017) Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18(6):812–822
Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU 3rd, Eary JF (2005) Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 103(2):339–348
Catton C, Davis A, Bell R, O’Sullivan B, Fornasier V, Wunder J, McLean M (1996c) Soft tissue sarcoma of the extremity. Limb salvage after failure of combined conservative therapy. Radiother Oncol 41(3):209–214
Karakousis CP, Proimakis C, Rao U, Velez AF, Driscoll DL (1996) Local recurrence and survival in soft-tissue sarcomas. Ann Surg Oncol 3(3):255–260
Ueda T, Yoshikawa H, Mori S, Araki N, Myoui A, Kuratsu S, Uchida A (1997) Influence of local recurrence on the prognosis of soft-tissue sarcomas. J Bone Joint Surg Br 79(4):553–557
Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T (1999) Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens – a European organization for research and treatment of cancer soft tissue and bone sarcoma group study. J Clin Oncol 17(1):150–157
Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos AP, van der Graaf WT, European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (2014) Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 15(4):415–423
Chawla SP, Papai Z, Mukhametshina G, Sankhala K, Vasylyev L, Fedenko A, Khamly K, Ganjoo K, Nagarkar R, Wieland S, Levitt DJ (2015) First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized clinical trial. JAMA Oncol 1(9):1272–1280
van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP (2012) Hohenberger P; EORTC soft tissue and bone sarcoma group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379(9829):1879–1886
Verschoor AJ, Gelderblom H (2014) Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series. Clin Sarcoma Res 1(4):14
Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D’Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR (2016) Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387(10028):1629–1637
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 34(8):786–793
D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, Streicher H (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19(3):416–426
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
de Matos, C.M.M. et al. (2019). Soft Tissue Sarcomas. In: De Mello, R., Mountzios, G., Tavares, Á. (eds) International Manual of Oncology Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-16245-0_35
Download citation
DOI: https://doi.org/10.1007/978-3-030-16245-0_35
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-16244-3
Online ISBN: 978-3-030-16245-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)